Novel role of the serine protease inhibitor elafin in gluten-related disorders

American Journal of Gastroenterology

Volumn 109, Issue 5, 2014, Pages 748-756

  Galipeau, Heather J ^a   Wiepjes, Michelle ^a   Motta, Jean Paul ^b,c,d   Schulz, Jessica D ^e   Jury, Jennifer ^a   Natividad, Jane M ^a   Pinto Sanchez, Ines ^a   Sinclair, Daniel ^a   Rousset, Perrine ^b,c,d   Martin Rosique, Rebeca ^f   Bermudez Humaran, Luis ^f   Leroux, Jean Christophe ^e   Murray, Joseph A ^g   Smecuol, Edgardo ^h   Bai, Julio C ^h   Vergnolle, Nathalie ^b,c,d   Langella, Philippe ^f   Verdu, Elena F ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b INSERM   (France)

^c CNRS   (France)

^d France   (France)

^e ETH ZURICH   (Switzerland)

^f UMR1319 MICALIS   (France)

^g MAYO CLINIC   (United States)

^h HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ELAFIN; GLIADIN; GLUTEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN ZO1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEAMINATION; ENTERITIS; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE BIOPSY; INTESTINE EPITHELIUM; KINETICS; LACTOCOCCUS LACTIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SMALL INTESTINE;

ADULT; ANIMALS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELIAC DISEASE; CHROMATOGRAPHY, LIQUID; DEAMINATION; DIET, GLUTEN-FREE; ELAFIN; FEMALE; GLIADIN; GTP-BINDING PROTEINS; HUMANS; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED NOD; MIDDLE AGED; PERMEABILITY; TRANSGLUTAMINASES; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84899919523     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.48     Document Type: Article

References (46)

1. Verdu EF. Editorial: can gluten contribute to irritable bowel syndrome. Am J Gastroenterol 2011; 106: 516-8.
2. Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. Am J Gastroenterol 2009; 104: 1587-94.
3. Biesiekierski JR, Newnham ED, Irving PM et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106: 508-14.
4. Ludvigsson JF, Leffler DA, Bai JC et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62: 43-52.
5. Pinier M, Fuhrmann G, Galipeau HJ et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 2012; 142: 316-25.
6. Hall N, Rubin G, Charnock A. Systematic review: adherence to a glutenfree diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009; 30: 315-30.
7. Lee A, Newman JM. Celiac diet: its impact on quality of life. J Am Diet Assoc 2003; 103: 1533-5.
8. Stevens L, Rashid M. Gluten-free and regular foods: a cost comparison. Can J Diet Pract Res 2008; 69: 147-50.
9. Hallert C, Sandlund O, Broqvist M. Perceptions of health-related quality of life of men and women living with coeliac disease. Scand J Caring Sci 2003; 17: 301-7.
10. Hallert C, Granno C, Hulten S et al. Living with coeliac disease: controlled study of the burden of illness. Scand J Gastroenterol 2002; 37: 39-42.
11. Black J, Orfila C. Impact of coeliac disease on dietary habits and quality of life. J Hum Nutr Diet 2011; 24: 582-7.
12. Ying QL, Simon SR. Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin. Biochemistry 1993; 32: 1866-74.
13. Ying QL, Simon SR. Kinetics of the inhibition of proteinase 3 by elafin. Am J Respir Cell Mol Biol 2001; 24: 83-9.
14. Williams S, Brown T, Roghanian A et al. SLPI and elafin: one glove, many fingers. Clin Sci 2006; 110: 21-35.
15. Schmid M, Fellermann K, Fritz P et al. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007; 81: 907-15.
16. Eriksson A, Jennische E, Flach CF et al. Real-time PCR quantification analysis of five mucosal transcripts in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2008; 20: 290-6.
17. Motta JP, Bermudez-Humaran LG, Deraison C et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012; 4: 158ra144.
18. Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem 1995; 270: 17702-11.
19. Baranger K, Zani M, Labas V et al. Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate. PloS ONE 2011; 6: e20976.
20. Kristiansen C, Madsen L, Fugger L et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4: 713-7.
21. Park D, Choi SS, Ha K. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 2010; 39: 619-31.
22. Sugai E, Moreno ML, Hwang HJ et al. Celiac disease serology in patients with Different pretest probabilities: Is biopsy avoidable? World J Gastroenterol 2010; 16: 3144-52.
23. Sugai E, Nachman F, Vaquez H et al. Dynamics of celiac disease-specific serology aft er initiation of a gluten-free diet and use in the assessment of compliance with treatment. Dig Liver Dis 2010; 42: 352-8.
24. Zubarev RA, Demirev PA, Haakansson P et al. Approaches and limits for accurate mass characterization of large biomolecules. Anal Chem 1995; 67: 3793-8.
25. Marietta E, Black K, Camilleri M et al. A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest 2004; 114: 1090-7.
26. Thomas KE, Sapone A, Fasano A et al. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol 2006; 176: 2512-21.
27. Galipeau HJ, Rulli NE, Jury J et al. Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice. J Immunol 2011; 187: 4338-46.
28. Natividad JM, Huang X, Slack E et al. Host responses to intestinal microbial antigens in gluten-sensitive mice. PLoS ONE 2009; 4: e6472.
29. Verdu EF, Huang X, Natividad J et al. Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice. Am J Physiol Gastrointest Liver Physiol 2008; 294: G217-25.
30. Silva MA, Jury J, Sanz Y et al. Increased bacterial translocation in glutensensitive mice is independent of small intestinal paracellular permeability defect. Dig Dis Sci 2012; 57: 38-47.
31. Biagi F, Luinetti O, Campanella J et al. Intraepithelial lymphocytes in the villous tip: do they indicate potential coeliac disease? J Clin Pathol 2004; 57: 835-9.
32. Motta JP, Magne L, Descamps D et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011; 140: 1272-82.
33. Finney S, Seale L, Sawyer RT et al. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J 1997; 324: 797-805.
34. Rubio-Tapia A, Ludvigsson JF, Brantner TL et al. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012; 107: 1538-44.
35. Ludvigsson JF, Rubio-Tapia A, van Dyke CT et al. Increasing incidence of celiac disease in a North American population. Am J Gastroenterol 2013; 108: 818-24.
36. Jabri B, Sollid LM. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 2009; 9: 858-70.
37. Klöck C, DiRaimondo TR, Khosla C. Role of transglutaminase 2 in celiac disease pathogenesis. Semin Immunopathol 2012; 34: 513-22.
38. Dafik L, Albertelli M, Stamnaes J et al. Activation and inhibition of transglutaminase 2 in mice. PloS ONE 2012; 7: e30642.
39. Johnson TN, Tanner MS, Taylor CJ et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001; 51: 451-60.
40. Lang CC, Brown RM, Kinirons MT et al. Decreased intestinal CYP3A in celiac disease: reversal aft er successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clin Pharmacol Ther 1996; 59: 41-6.
41. Zani ML, Tanga A, Saidi A et al. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions. Biochem Soc Trans 2011; 39: 1441-6.
42. Guyot N, Zani M, Maurel M et al. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 2005; 44: 15610-8.
43. Shan L, Molberg Ø, Parrot I et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297: 2275-9.
44. Wang Z, Griffin M. TG2, a novel extracellular protein with multiple functions. Amino Acids 2012; 42: 939-49.
45. Alam SR, Newby DE, Henriksen PA. Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium. Biochem Pharmacol 2012; 83: 695-704.
46. DePaolo RW, Abadie V, Tang F et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011; 471: 220-4.